Medicago completes a key milestone with success!

Medicago Successfully Completes the Production of More Than Ten Million Doses of H1N1 VLP Influenza Vaccine in One Month

by Émilie Pelletier on 24 July 2012

Tags : medicago

DURHAM, NC and QUEBEC CITY, QC, July 24, 2012 /CNW/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful completion of a key milestone under an agreement with the Defense Advanced Research Projects Agency (DARPA). The milestone was the production of at least 10 million doses of H1N1 VLP influenza vaccine candidate in one month ("rapid fire test").   This rapid fire test was conducted at Medicago's facility in Durham, North Carolina.

As part of the rapid fire test, production of the H1N1 VLP influenza vaccine candidate began on March 25th, 2012, and was completed in 30 days on April 24th, 2012.  The production lots were then tested by a third party laboratory to confirm both the immunogenicity of the vaccine candidate and the number of doses produced.  Testing confirmed that a single dose of the H1N1 VLP influenza vaccine candidate induced protective levels of neutralizing antibodies in an animal model.  Significantly more than 10 million doses, as defined by the testing conditions, were confirmed.

"The completion of the rapid fire test marks a substantial achievement in demonstrating our technology and the potential for Medicago to be the first responder in the event of a pandemic flu outbreak," said Andy Sheldon, Chief Executive Officer of Medicago.  "We look forward to continuing to move our company closer to commercial capability in the near future."


>>> Read the press release

Share

Comments

Post a comment +